Profusa (NASDAQ:PFSA) Major Shareholder Sells $37,745.79 in Stock

Profusa, Inc. (NASDAQ:PFSA) major shareholder Financial Lp Hrt sold 42,411 shares of the firm’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $0.89, for a total transaction of $37,745.79. Following the completion of the transaction, the insider directly owned 74,198 shares of the company’s stock, valued at approximately $66,036.22. This represents a 36.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Wednesday, August 12th, Financial Lp Hrt acquired 5,585 shares of Profusa stock. The shares were bought at an average cost of $0.96 per share, for a total transaction of $5,361.60.
• On Tuesday, August 4th, Financial Lp Hrt acquired 1,368 shares of Profusa stock. The shares were bought at an average cost of $0.95 per share, for a total transaction of $1,299.60.
• On Monday, August 3rd, Financial Lp Hrt bought 14,556 shares of Profusa stock. The stock was purchased at an average cost of $0.96 per share, for a total transaction of $13,973.76.
• On Wednesday, July 29th, Financial Lp Hrt bought 1,310 shares of Profusa stock. The stock was purchased at an average price of $1.01 per share, with a total value of $1,323.10.

Profusa Stock Performance

Shares of PFSA opened at $0.90 on Monday. The stock has a 50-day moving average of $2.73 and a two-hundred day moving average of $23.78. Profusa, Inc. has a one year low of $0.81 and a one year high of $1,297.50. The stock has a market cap of $170,962.00, a P/E ratio of -0.00 and a beta of 0.52.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Profusa in a research note on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Profusa Company Profile

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.